Garson Chan1,2, Liang G Qu3, Johan Gani3,4. 1. Department of Urology, Austin Health, University of Melbourne, 145 Studley Road, Heidelberg, VIC, 3084, Australia. garsonkchan@gmail.com. 2. Division of Urology, Department of Surgery, University of Saskatchewan, Saskatoon, Canada. garsonkchan@gmail.com. 3. Department of Urology, Austin Health, University of Melbourne, 145 Studley Road, Heidelberg, VIC, 3084, Australia. 4. Department of Urology, Western Health, University of Melbourne, Melbourne, Australia.
Abstract
PURPOSE: Sacral neuromodulation (SNM) is one of the few management options shown to improve outcomes in patients with detrusor underactivity (DU). This original research will investigate if preserved bladder contractility can predict a successful treatment with SNM. METHODS: This is a retrospective study of a prospectively collected database of consecutive patients with DU, who had a staged SNM trial from January 2013 to December 2018, with a minimum of 12 months follow-up. The primary outcome was the success of stage 1 SNM trial. RESULTS: In total, 69 patients with DU were followed. The median age was 67 [interquartile range (IQR) 74-55], median baseline bladder contractility index (BCI) 18 (IQR 67-0), and median post-void residual 200 mL (IQR 300-130). There were 35 patients (51%) that responded to a SNM trial. At a median follow-up of 23 months (IQR 39-12), three were removed for poor efficacy. In patients with detrusor acontractility (DAC), six responded (33%), compared to 29 patients (57%) with BCI > 0. This was statistically significant, p value 0.03. Younger age was also a predictive factor for SNM response, p value 0.02. There were no differences noted in those with gender, neurogenic history, previous pelvic surgery, diabetes, or pre-operative voiding history. CONCLUSION: Our study showed that patients with preserved bladder contractility are more likely to respond to a trial of SNM compared with those that have DAC. Younger age was also predictive of SNM response. UDS is the only method to accurately identify DAC patients. This information will help in patient selection and pre-operative counselling.
PURPOSE: Sacral neuromodulation (SNM) is one of the few management options shown to improve outcomes in patients with detrusor underactivity (DU). This original research will investigate if preserved bladder contractility can predict a successful treatment with SNM. METHODS: This is a retrospective study of a prospectively collected database of consecutive patients with DU, who had a staged SNM trial from January 2013 to December 2018, with a minimum of 12 months follow-up. The primary outcome was the success of stage 1 SNM trial. RESULTS: In total, 69 patients with DU were followed. The median age was 67 [interquartile range (IQR) 74-55], median baseline bladder contractility index (BCI) 18 (IQR 67-0), and median post-void residual 200 mL (IQR 300-130). There were 35 patients (51%) that responded to a SNM trial. At a median follow-up of 23 months (IQR 39-12), three were removed for poor efficacy. In patients with detrusor acontractility (DAC), six responded (33%), compared to 29 patients (57%) with BCI > 0. This was statistically significant, p value 0.03. Younger age was also a predictive factor for SNM response, p value 0.02. There were no differences noted in those with gender, neurogenic history, previous pelvic surgery, diabetes, or pre-operative voiding history. CONCLUSION: Our study showed that patients with preserved bladder contractility are more likely to respond to a trial of SNM compared with those that have DAC. Younger age was also predictive of SNM response. UDS is the only method to accurately identify DAC patients. This information will help in patient selection and pre-operative counselling.
Authors: Anna E R Faris; Bradley C Gill; Javier Pizarro-Berdichevsky; Elodi Dielubanza; Marisa M Clifton; Henry Okafor; Howard B Goldman; Courtenay K Moore; Raymond R Rackley; Sandip P Vasavada Journal: J Urol Date: 2017-02-10 Impact factor: 7.450
Authors: Philip E V van Kerrebroeck; Anco C van Voskuilen; John P F A Heesakkers; August A B Lycklama á Nijholt; Steven Siegel; U Jonas; Clare J Fowler; Magnus Fall; Jerzy B Gajewski; Magdy M Hassouna; Francesco Cappellano; Mostafa M Elhilali; Douglas F Milam; Anurag K Das; H E Dijkema; Ubi van den Hombergh Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: M Hohenfellner; J Humke; C Hampel; S Dahms; K Matzel; S Roth; J W Thüroff; D Schultz-Lampel Journal: Urology Date: 2001-12 Impact factor: 2.649
Authors: Karl-Dietrich Sievert; Bastian Amend; G Gakis; P Toomey; A Badke; H P Kaps; Arnulf Stenzl Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: U Jonas; C J Fowler; M B Chancellor; M M Elhilali; M Fall; J B Gajewski; V Grünewald; M M Hassouna; U Hombergh; R Janknegt; P E van Kerrebroeck; A A Lylcklama a Nijeholt; S W Siegel; R A Schmidt Journal: J Urol Date: 2001-01 Impact factor: 7.450
Authors: Kevin L Rademakers; Jamie M Drossaerts; Philip E van Kerrebroeck; Matthias Oelke; Gommert A van Koeveringe Journal: Neurourol Urodyn Date: 2016-04-06 Impact factor: 2.696
Authors: Jamie Drossaerts; Kevin Rademakers; Gommert van Koeveringe; Philip Van Kerrebroeck Journal: World J Urol Date: 2015-02-14 Impact factor: 4.226